Antiplatelet Therapy During Heparin Drip for Acute Limb Ischemia

Immediate Management Approach

All patients presenting with acute limb ischemia require immediate initiation of therapeutic heparin anticoagulation to prevent clot propagation and further embolism, with a recommended initial bolus of 60 U/kg (maximum 4000 U) followed by continuous infusion at 12 U/kg/hr (maximum 1000 U/hr), targeting aPTT of 1.5-2.0 times control (approximately 50-70 seconds) 2, 3, 4
The American College of Chest Physicians recommends that patients already receiving antiplatelet therapy for symptomatic peripheral arterial disease should continue their aspirin (75-100 mg daily) or clopidogrel (75 mg daily) without interruption 1, 5

Antiplatelet therapy reduces major adverse cardiovascular events (MACE) in all patients with symptomatic peripheral arterial disease, which includes those presenting with acute limb ischemia 1, 2
The combination of anticoagulation and antiplatelet therapy addresses both the acute thrombotic event and the underlying atherosclerotic disease process 1

Patients already on antiplatelet therapy should continue their current single antiplatelet agent (aspirin or clopidogrel) unchanged while initiating heparin, and not add a second antiplatelet agent 1, 5
Patients not previously on antiplatelet therapy should initiate aspirin 75-100 mg daily alongside heparin anticoagulation 1

The American College of Chest Physicians recommends against discontinuing antiplatelet therapy when starting heparin, as the cardiovascular protective effects remain essential 1
Dual antiplatelet therapy (aspirin plus clopidogrel) is not recommended for routine peripheral arterial disease management, as it increases bleeding risk without proven benefit 1

Monitor platelet counts daily to detect heparin-induced thrombocytopenia, which can paradoxically worsen limb ischemia 4
Wound hematomas are the most common bleeding complication when combining anticoagulation with antiplatelet therapy in the perioperative setting 3

Maintain antiplatelet therapy indefinitely for long-term cardiovascular risk reduction, according to the American College of Chest Physicians 1
After acute management, transition to single antiplatelet therapy as the standard long-term regimen, as recommended by the American College of Chest Physicians 1